Hims & Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat

Comments
Loading...
Zinger Key Points

Hims & Hers Health Inc. HIMS reported its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter. 

The Details: Hims & Hers Health reported quarterly GAAP earnings of 11 cents per share, which met the analyst consensus estimate. Quarterly revenue came in at $481.14 million, which beat the analyst consensus estimate of $470.31 million and is an increase over revenue of $246.62 million from the same period last year.

Hims & Hers subscribers grew to 2.2 million, up 45% year-over-year in 2024. Gross margin was 77% for the fourth quarter of 2024 compared to 83% for the fourth quarter of 2023.

Read Next: Palantir Extends Losses, Microsoft Slides: What’s Driving Markets Monday? 

“2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, Hims & Hers Health CEO.

“Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health — with thousands more joining daily,” Dudum added.

Outlook: For the first quarter of 2025, Hims and Hers expects revenue of $520 million to $540 million and adjusted EBITDA of $55 million to $65 million, reflecting an adjusted EBITDA margin of 11% to 12%.

For the full year 2025, the company expects revenue of $2.3 billion to $2.4 billion and adjusted EBITDA of $270 million to $320 million, reflecting an adjusted EBITDA margin of 12% to 13%.

HIMS Price Action: According to data from Benzinga Pro, Hims & Hers Health shares are down 17.66% after hours at $42.25 Monday.  

Read Next: 

Image: Shutterstock

HIMS Logo
HIMSHims & Hers Health Inc
$27.231.57%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
97.21
Growth
94.75
Quality
-
Value
12.07
Price Trend
Short
Medium
Long
Got Questions? Ask
Which healthcare stocks will benefit from Hims' growth?
How could telehealth providers exploit Hims' subscriber increase?
Which technology firms are aligned with Hims' platform?
Will investors favor personalized healthcare solutions now?
How might pharmaceutical companies react to Hims' revenue growth?
Which emerging health tech startups could compete with Hims?
Could retail investors find opportunities in Hims' dip?
How does Hims' EBITDA outlook influence market sentiment?
Which healthcare ETFs should investors consider now?
What trends in personalized medicine could emerge from Hims' success?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: